enGene Therapeutics Inc. Cost, Maintenance
enGene Therapeutics Inc. (ENGN) had Cost, Maintenance of $50.00 thousand as of 2020-04-10, per its 10-Q filed 2026-09-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostMaintenance · last filed 2026-09-08
- 2020-04-10: Cost, Maintenance $50.00K.
| Period end | Cost, Maintenance |
|---|---|
| 2020-04-10 | $50.00K 10-Q · filed 2026-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |